Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LBR-101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LBR-101 IV Dose 1 | EXPERIMENTAL | LBR-101 Dose 1 Administered Intravenously |
| LBR-101 SC Dose 1 | EXPERIMENTAL | LBR-101 Dose 1 Administered Subcutaneously |
| Placebo IV | PLACEBO_COMPARATOR | Placebo Administered Intravenously |
| Placebo SC | PLACEBO_COMPARATOR | Placebo Administered Subcutaneously |
| LBR-101 Dose 2 IV | EXPERIMENTAL | LBR-101 Dose 2 Administered Intravenously |
| LBR-101 Dose 2 SC | EXPERIMENTAL | LBR-101 Dose 2 Administered Subcutaneously |
| Name | Type | Description |
|---|---|---|
| LBR-101 IV | BIOLOGICAL | LBR-101 Administered Intravenously |
| LBR-101 SC | BIOLOGICAL | LBR-101 Administered Subcutaneously |
Inclusion Criteria: * Generally Healthy, Signed Approved Informed Consent, BMI 17.5-34.5 kg/m2, Willing and able to comply with CRU rules regulations and study schedule Exclusion Criteria: * Clinically significant medical or psychiatric condition, Febrile illness within 5 days of dosing, Pregnant...
LBR-101 is a monoclonal antibody being studied for bioavailability and pharmacokinetics. It is in Phase 1 clinical development, with a completed trial evaluating its safety and bioavailability when given intravenously and subcutaneously. The study involved healthy volunteers in the United States.
LBR-101 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied for its bioavailability and pharmacokinetic properties in a Phase 1 clinical trial.
LBR-101 is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The drug is currently in Phase 1 clinical development.
LBR-101 is in Phase 1 clinical development. One Phase 1 trial has been completed, which studied the safety and bioavailability of the drug when administered intravenously and subcutaneously in healthy volunteers.
LBR-101 has one completed clinical trial, NCT01991509, titled 'Safety and Bioavailability of IV and SC LBR-101'. This Phase 1 study enrolled 36 participants in the United States and was placebo-controlled, randomized, and double-blind.
LBR-101 is a distinct investigational monoclonal antibody. No alternative names for LBR-101 have been reported. It is being studied for its bioavailability and pharmacokinetics in early-stage clinical trials.